| Diabetic Retinopathy
Iluvien vs Lucentis
Side-by-side clinical, coverage, and cost comparison for diabetic retinopathy.Deep comparison between: Iluvien vs Lucentis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLucentis has a higher rate of injection site reactions vs Iluvien based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lucentis but not Iluvien, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Iluvien
Lucentis
At A Glance
Intravitreal injection
Corticosteroid
Intravitreal injection
Monthly
VEGF-A antagonist
Indications
- Diabetic Retinopathy
- Uveitis
- Exudative age-related macular degeneration
- Macular retinal edema
- Macular edema due to diabetes mellitus
- Diabetic Retinopathy
- Myopic choroidal neovascularization
Dosing
Diabetic Retinopathy, Uveitis Single 0.19 mg (190 mcg) fluocinolone acetonide intravitreal implant injected under aseptic conditions via a preloaded single-use applicator; optimal placement is inferior to the optic disc and posterior to the equator, with needle entry 4 mm inferotemporal from the limbus.
Exudative age-related macular degeneration 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly; less frequent dosing with regular assessment may be considered after 3-4 initial monthly doses.
Macular retinal edema 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly.
Macular edema due to diabetes mellitus, Diabetic Retinopathy 0.3 mg (0.05 mL of 6 mg/mL) intravitreal injection once monthly.
Myopic choroidal neovascularization 0.5 mg (0.05 mL of 10 mg/mL) intravitreal injection once monthly for up to 3 months; retreat as needed.
Contraindications
- Active or suspected ocular or periocular infections, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases
- Glaucoma with cup to disc ratio greater than 0.8
- Known hypersensitivity to any components of ILUVIEN
- Ocular or periocular infections
- Known hypersensitivity to ranibizumab or any excipient in LUCENTIS
Adverse Reactions
Most common (>=1%) Cataract, increased intraocular pressure, myodesopsia, eye pain, conjunctival haemorrhage, posterior capsule opacification, eye irritation, vitreous detachment, conjunctivitis, corneal oedema, ocular hyperaemia, anemia, headache, renal failure, pneumonia
Serious Optic nerve damage, visual acuity and field defects, secondary ocular infections including herpes simplex, perforation of the globe where there is thinning of the cornea or sclera
Postmarketing Drug administration error, drug ineffectiveness
Most common Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, vitreous detachment, intraocular inflammation, cataract, foreign body sensation in eyes, eye irritation, lacrimation increased, nasopharyngitis, headache
Serious Endophthalmitis, retinal detachment, rhegmatogenous retinal detachment, iatrogenic traumatic cataract, thromboembolic events, fatal events in patients with DME and DR
Postmarketing Tear of retinal pigment epithelium in patients with neovascular AMD
Pharmacology
Fluocinolone acetonide is a synthetic corticosteroid that inhibits inflammatory responses by blocking phospholipase A2 via lipocortins, suppressing biosynthesis of prostaglandins and leukotrienes and reducing edema, leukocyte migration, capillary proliferation, and fibroblast proliferation.
Ranibizumab is a VEGF-A antagonist; a recombinant humanized IgG1 kappa monoclonal antibody fragment that binds to active forms of VEGF-A, preventing interaction with VEGFR1 and VEGFR2 on endothelial cells, thereby reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Iluvien
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (0/12)
Lucentis
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (0/12)
UnitedHealthcare
Iluvien
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lucentis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Iluvien
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lucentis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25
Iluvien CoPay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Inherited Retinal Diseases - Public Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IluvienView full Iluvien profile
LucentisView full Lucentis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.